Literature DB >> 23638306

SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.

Libo Zheng1, Xiaolan Zhang, Jeremy Chen, Ryan Ichikawa, Kori Wallace, Charalabos Pothoulakis, Hon Wai Koon, Stephan R Targan, David Q Shih.   

Abstract

TL1A is a member of the TNF superfamily, and its expression is increased in the mucosa of inflammatory bowel disease patients. Moreover, patients with certain TNFSF15 variants over-express TL1A and have a higher risk of developing strictures in the small intestine. Consistently, mice with sustained Tl1a expression in either lymphoid or myeloid cells develop spontaneous ileitis and increased intestinal collagen deposition. Transgenic (Tg) mice with constitutive Tl1a expression in both lymphoid and myeloid cells were generated to assess their in vivo consequence. Constitutive expression of Tl1a in both lymphoid and myeloid cells showed increased spontaneous ileitis and collagen deposition than WT mice. T cells with constitutive expression of Tl1a in both lymphoid and myeloid cells were found to have a more activated phenotype, increased gut homing marker CCR9 expression, and enhanced Th1 and Th17 cytokine activity than WT mice. Although no differences in T cell activation marker, Th1 or Th17 cytokine activity, ileitis, or collagen deposition were found between constitutive Tl1a expression in lymphoid only, myeloid only, or combined lymphoid and myeloid cells. Double hemizygous Tl1a-Tg mice appeared to have worsened ileitis and intestinal fibrosis. Our findings confirm that TL1A-DR3 interaction is involved in T cell-dependent ileitis and fibrosis.

Entities:  

Keywords:  fibrosis; ileitis; mucosal inflammation; transgenic

Year:  2013        PMID: 23638306      PMCID: PMC3638202          DOI: 10.1556/EuJMI.3.2013.1.2

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  42 in total

Review 1.  Insights into TL1A and IBD pathogenesis.

Authors:  David Q Shih; Kathrin S Michelsen; Robert J Barrett; Eva Biener-Ramanujan; Rivkah Gonsky; Xiaolan Zhang; Stephan R Targan
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

2.  Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes.

Authors:  Konstantinos A Papadakis; Daocheng Zhu; John L Prehn; Carol Landers; Armine Avanesyan; Gina Lafkas; Stephan R Targan
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.

Authors:  Thi Sau Migone; Jun Zhang; Xia Luo; Li Zhuang; Cecil Chen; Bugen Hu; June S Hong; James W Perry; Su Fang Chen; Joe X H Zhou; Yun Hee Cho; Stephen Ullrich; Palanisamy Kanakaraj; Jeffrey Carrell; Ernest Boyd; Henrik S Olsen; Gang Hu; Laurie Pukac; Ding Liu; Jian Ni; Sunghee Kim; Reiner Gentz; Ping Feng; Paul A Moore; Steve M Ruben; Ping Wei
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

4.  CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING.

Authors:  O Cohavy; D Q Shih; T M Doherty; C F Ware; S R Targan
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-03

5.  Toll-like receptor 9-induced type I IFN protects mice from experimental colitis.

Authors:  Kyoko Katakura; Jongdae Lee; Daniel Rachmilewitz; Gloria Li; Lars Eckmann; Eyal Raz
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

6.  The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system.

Authors:  K A Papadakis; J Prehn; V Nelson; L Cheng; S W Binder; P D Ponath; D P Andrew; S R Targan
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

7.  Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis.

Authors:  Daniel Rachmilewitz; Fanny Karmeli; Shimon Shteingart; Jongdae Lee; Kenji Takabayashi; Eyal Raz
Journal:  Inflamm Bowel Dis       Date:  2006-05       Impact factor: 5.325

Review 8.  Insights into IBD Pathogenesis.

Authors:  David Q Shih; Stephan R Targan
Journal:  Curr Gastroenterol Rep       Date:  2009-12

9.  Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease.

Authors:  Giorgos Bamias; Charles Martin; Marco Marini; Sharon Hoang; Margarita Mishina; William G Ross; Muhammadreza A Sachedina; Charles M Friel; James Mize; Stephen J Bickston; Theresa T Pizarro; Ping Wei; Fabio Cominelli
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

10.  The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation.

Authors:  F Meylan; Y-J Song; I Fuss; S Villarreal; E Kahle; I-J Malm; K Acharya; H L Ramos; L Lo; M M Mentink-Kane; T A Wynn; T-S Migone; W Strober; R M Siegel
Journal:  Mucosal Immunol       Date:  2010-10-27       Impact factor: 7.313

View more
  13 in total

Review 1.  Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.

Authors:  Shuvra Ray; Carlo De Salvo; Theresa T Pizarro
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

Review 2.  Immunopathology of inflammatory bowel disease.

Authors:  Kori L Wallace; Li-Bo Zheng; Yoshitake Kanazawa; David Q Shih
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.

Authors:  Jim G Castellanos; Viola Woo; Monica Viladomiu; Gregory Putzel; Svetlana Lima; Gretchen E Diehl; Andrew R Marderstein; Jorge Gandara; Alexendar R Perez; David R Withers; Stephan R Targan; David Q Shih; Ellen J Scherl; Randy S Longman
Journal:  Immunity       Date:  2018-12-11       Impact factor: 31.745

Review 4.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

5.  Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Authors:  D Q Shih; L Zheng; X Zhang; H Zhang; Y Kanazawa; R Ichikawa; K L Wallace; J Chen; C Pothoulakis; H W Koon; S R Targan
Journal:  Mucosal Immunol       Date:  2014-05-21       Impact factor: 7.313

6.  Protective association of tumor necrosis factor superfamily 15 (TNFSF15) polymorphic haplotype with Ulcerative Colitis and Crohn's disease in an Indian population.

Authors:  Kirankumar Baskaran; Srinivasan Pugazhendhi; Balakrishnan S Ramakrishna
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

7.  Death Receptor 3 regulates distinct pathological attributes of acute versus chronic murine allergic lung inflammation.

Authors:  Ravinder Kaur Singh; William Victor Perks; Jason Peter Twohig; Emma J Kidd; Kenneth Broadley; Stuart N Farrow; Anwen Sian Williams; Philip Russel Taylor; Eddie Chung Yern Wang
Journal:  Cell Immunol       Date:  2017-09-15       Impact factor: 4.868

8.  Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome.

Authors:  Noam Jacob; Jonathan P Jacobs; Kotaro Kumagai; Connie W Y Ha; Yoshitake Kanazawa; Venu Lagishetty; Katherine Altmayer; Ariel M Hamill; Aimee Von Arx; R Balfour Sartor; Suzanne Devkota; Jonathan Braun; Kathrin S Michelsen; Stephan R Targan; David Q Shih
Journal:  Mucosal Immunol       Date:  2018-07-09       Impact factor: 7.313

Review 9.  Innate Lymphoid Cells in Crohn's Disease.

Authors:  Ying Wu; Jun Shen
Journal:  Front Immunol       Date:  2020-11-16       Impact factor: 7.561

Review 10.  Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs.

Authors:  Shukai Zhan; Na Li; Caiguang Liu; Ren Mao; Dongxuan Wu; Tong Li; Minhu Chen; Xiaojun Zhuang; Zhirong Zeng
Journal:  Front Microbiol       Date:  2021-07-16       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.